Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
Published: November 03, 2025 by: CNBC
Sentiment: Negative
Pfizer said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive. The new suit escalates a heated standoff between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the blockbuster weight loss drug market.
Read More
Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera
Published: November 03, 2025 by: WSJ
Sentiment: Negative
Lawsuit says the proposed merger of the weight-loss drugmakers could kill off a smaller competitor.
Read More
Novo Nordisk changes tack with bold raid on Pfizer obesity deal
Published: October 30, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the weight-loss drug market under a new CEO and board.
Read More
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
Published: October 30, 2025 by: Benzinga
Sentiment: Negative
On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).
Read More
Invesco EQV International Equity Fund Q3 2025 Performance Update
Published: October 30, 2025 by: Seeking Alpha
Sentiment: Positive
Invesco EQV International Equity Fund's Q3 2025 performance was driven by strong returns from TSM, Legrand, Trip.com, and Shenzhen Inovance. TSM outperformed on robust AI chip demand and favorable margins, while Legrand benefited from data center growth and Trip.com from travel recovery. Key detractors included Shimano, RELX, and London Stock Exchange, impacted by margin pressures, AI disruption concerns, and rising competition.
Read More
Novo Nordisk: Decade-Low Valuation Meets A Billion-Patient Market
Published: October 24, 2025 by: Seeking Alpha
Sentiment: Positive
Initiating coverage on Novo Nordisk (NVO) with a Strong Buy 70% below its all-time high. NVO's competitive pressures and US political pricing risks are mid-term noise. Global obesity and diabetes markets remain vastly underpenetrated. Valuation is at multi-decade lows, with a TTM P/E of 13-14x versus a 20-year average of 23x, and even below the pre semaglutide-boom average of 21x.
Read More
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.
Read More
Novo Nordisk: The fog begins to lift
Published: October 24, 2025 by: Proactive Investors
Sentiment: Positive
It has been a jittery few months for Novo Nordisk (NYSE:NVO) investors, but Berenberg thinks the worst of the uncertainty may be passing. The broker has reiterated its 'buy' rating and DKK 425 price target, arguing that a run of upcoming announcements should bring long-awaited clarity to the debate over pricing, demand and leadership at the Danish drugmaker.
Read More
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Negative
Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded drug headwinds.
Read More
NVO Stock Falls Amid Governance Shift as Foundation Seeks New Board
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Negative
Novo Nordisk stock slides as the Novo Nordisk Foundation pushes a sweeping board overhaul, signaling a new era in governance and strategic direction.
Read More
The Ozempic maker shakes up its board. It has been a year of turmoil for Novo Nordisk.
Published: October 21, 2025 by: Market Watch
Sentiment: Negative
Ozempic maker Novo Nordisk is shaking up its board.
Read More
Novo Nordisk in active talks with Trump administration on MFN
Published: October 21, 2025 by: CNBC Television
Sentiment: Positive
Novo Nordisk U.S. President Dave Moore confirms the company is in active discussions with the Trump administration over most favored nation pricing for its popular GLP-1 drugs Ozempic and Wegovy, as it wraps up talks for the IRA Medicare drug price negotiations. It comes as the company is ramping up its U.S. manufacturing capabilities ahead of the anticipated approval of Wegovy in pill form.
Read More
Novo Nordisk board members step down after clash with controlling shareholder
Published: October 21, 2025 by: CNBC
Sentiment: Negative
Novo Nordisk directors and the firm's controlling shareholder failed to reach an agreement on the future composition of the board.
Read More
Novo Nordisk Chair Helge Lund and six other board members to step down
Published: October 21, 2025 by: Reuters
Sentiment: Neutral
Wegovy-maker Novo Nordisk said on Tuesday its Chair Helge Lund and six other board members will step down at an upcoming extraordinary general meeting on November 14.
Read More
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Oct 2025)
Published: October 21, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Ozempic has become a phenomenon, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Read More
Insight: Novo Nordisk fights to keep Medicaid paying for weight-loss drugs
Published: October 21, 2025 by: Reuters
Sentiment: Neutral
Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as some U.S. states struggle with the treatment's costs, according to state documents, company emails and interviews with lawmakers and advocates.
Read More
My Top 3 Pharma Stocks
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.
Read More
2 Beaten-Down Stocks to Buy and Hold for the Next Decade
Published: October 20, 2025 by: The Motley Fool
Sentiment: Positive
The market is forward-looking, but investors who earn better-than-average returns often look even further into the future and identify opportunities that are currently being overlooked. That means, among other things, buying shares of companies that are lagging the market but can bounce back over the midterm and beyond.
Read More
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the feasibility of such a development.
Read More
Here's What Trump Said That's Pressuring Novo Nordisk and Eli Lilly Stocks
Published: October 17, 2025 by: Investopedia
Sentiment: Negative
Novo Nordisk (NVO) and Eli Lilly (LLY) shares slumped in early trading Friday after President Trump promised to lower the prices of popular weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Lilly's Zepbound.
Read More
Is Trump Going to Kill the GLP-1 Cash Cow?
Published: October 17, 2025 by: 24/7 Wall Street
Sentiment: Negative
GLP-1 drugs propelled Novo Nordisk (NVO) and Eli Lilly (LLY) to record profits, with sales exceeding $20 billion amid skyrocketing demand. Both companies cut prices recently to expand access, but President Trump's vow threatens deeper reductions.
Read More
Novo Nordisk, Eli Lilly shares drop as Trump promises lower weight loss drug prices
Published: October 17, 2025 by: Proactive Investors
Sentiment: Negative
Shares of Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY), two major pharmaceutical companies that produce weight-loss drugs, dropped sharply following comments from US president Donald Trump about reductions in the prices of these medicines. During a White House event focused on fertility treatments and drug pricing, Trump suggested that the cost of drugs like Novo Nordisk's Ozempic (semaglutide), used for diabetes and weight management, would soon be “much lower.
Read More
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.
Read More
Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case
Published: October 16, 2025 by: Seeking Alpha
Sentiment: Positive
Omeros Corporation's stock surged over 150% after licensing zaltenibart to Novo Nordisk for $340M upfront, plus milestones and royalties. The deal provides OMER with critical funding, alleviating bankruptcy concerns and supporting operations through 2027 as it pursues FDA approval for narsoplimab. Zaltenibart's unique MASP-3 inhibition offers advantages in PNH, attracting NVO, which seeks to diversify beyond semaglutide amid recent headwinds.
Read More
Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.
Read More
Novo Nordisk begins round of layoffs in United States, sources say
Published: October 15, 2025 by: Reuters
Sentiment: Negative
Drugmaker Novo Nordisk has begun a round of layoffs in its most important market, the United States, with affected staff set to be notified between this week and next, according to an email and two sources familiar with the matter.
Read More
Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug
Published: October 15, 2025 by: WSJ
Sentiment: Positive
Under the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialize zaltenibart.
Read More
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Novo Nordisk halts work on cell therapy for diabetes to cut costs, Bloomberg News reports
Published: October 10, 2025 by: Reuters
Sentiment: Negative
Novo Nordisk has cut its cell therapy division, which has been trying to find a cure for type 1 diabetes, Bloomberg News reported on Friday, citing a statement.
Read More
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406